Exact Sciences shares plunged Wednesday after the company reported widening losses. The maker of the Cologuard colon cancer screening test lowered its full-year outlook. CEO Kevin Conroy said the ...

The maker of the Cologuard colon cancer screening test lowered its full-year outlook. CEO Kevin Conroy said the firm's quarterly execution and forecast don't reflect its full potential.

There is always the chance the item you purchased does not live up to your expectations, or, you may want to return the gifts ...

The biomedical giant best known for its Cologuard at-home colon cancer screening test reported a loss of $38.2 million, or $0.21 per share, on revenue of $708.7 million. The average estimate of six ...

The maritime industry, a cornerstone of global trade, is undergoing a significant transformation through the adoption of digitalization and smart shipping technologies. As the industry navigates ...

That could help the healthcare stock stage a comeback. Per the findings of the pivotal BLUE-C study, the Cologuard Plus test of Exact Sciences stands out for its high sensitivity at a specificity ...

Discover the secrets of Radio 4's iconic forecast for the seas around the British Isles.

The global shipping industry is constantly evolving, and the COVID-19 pandemic began a marked shift in how container shipping operates. Disruption caused by the pandemic has forced the industry to ...

Movements are published at midday the working day before and will be updated by the Movements team until the end of each working day.